Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. (Q35632848)

9 August 2017

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. (English)

1 reference

9 August 2017

1 reference

Nallasivam Palanisamy

object named as

Nallasivam Palanisamy

26

0 references

Mark Rubin

object named as

Mark A Rubin

18

0 references

Arul Chinnaiyan

30

object named as

Arul M Chinnaiyan

1 reference

9 August 2017

Scott A Tomlins

1

1 reference

9 August 2017

Sheila M J Aubin

2

1 reference

9 August 2017

Javed Siddiqui

3

1 reference

9 August 2017

Robert J Lonigro

4

1 reference

9 August 2017

Laurie Sefton-Miller

5

1 reference

9 August 2017

Siobhan Miick

6

1 reference

9 August 2017

Sarah Williamsen

7

1 reference

9 August 2017

Petrea Hodge

8

1 reference

9 August 2017

Jessica Meinke

9

1 reference

9 August 2017

Amy Blase

10

1 reference

9 August 2017

Yvonne Penabella

11

1 reference

9 August 2017

John R Day

12

1 reference

9 August 2017

Radhika Varambally

13

1 reference

9 August 2017

Bo Han

14

1 reference

9 August 2017

David Wood

15

1 reference

9 August 2017

Lei Wang

16

1 reference

9 August 2017

Martin G Sanda

17

1 reference

9 August 2017

Daniel R Rhodes

19

1 reference

9 August 2017

Brent Hollenbeck

20

1 reference

9 August 2017

Kyoko Sakamoto

21

1 reference

9 August 2017

Jonathan L Silberstein

22

1 reference

9 August 2017

Yves Fradet

23

1 reference

9 August 2017

James B Amberson

24

1 reference

9 August 2017

Stephanie Meyers

25

1 reference

9 August 2017

Harry Rittenhouse

27

1 reference

9 August 2017

John T Wei

28

1 reference

9 August 2017

Jack Groskopf

29

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

Science Translational Medicine

9 August 2017

1 reference

9 August 2017

3

1 reference

9 August 2017

94

1 reference

9 August 2017

94ra72

1 reference

Prostate cancer screening: current status and future perspectives.

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Antibody-based detection of ERG rearrangement-positive prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Development of personalized tumor biomarkers using massively parallel sequencing

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Screening and prostate-cancer mortality in a randomized European study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Mortality results from a randomized prostate-cancer screening trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

An updated catalog of prostate cancer predictive tools

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Saturation biopsies on autopsied prostates for detecting and characterizing prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Decision curve analysis: a novel method for evaluating prediction models

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Use of extended pattern technique for initial prostate biopsy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

DD3: a new prostate-specific gene, highly overexpressed in prostate cancer

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

PCA3: a molecular urine assay for predicting prostate biopsy outcome

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Development and external validation of an extended 10-core biopsy nomogram

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Prevalence and characteristics of screen-detected prostate carcinomas at low prostate-specific antigen levels: aggressive or insignificant?

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245713

Needle Biopsies on Autopsy Prostates: Sensitivity of Cancer Detection Based on True Prevalence

25 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001970

Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21813756

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21813756

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prostate cancer volume at biopsy predicts clinically significant upgrading

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21813756

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1126/SCITRANSLMED.3001970

1 reference

9 August 2017

1 reference

9 August 2017

1 reference